Llwytho...
Prolonged benefit from ipilimumab correlates with improved outcomes from subsequent pembrolizumab
Patients with metastatic melanoma who progress on ipilimumab can clearly derive benefit to subsequent anti-PD-1 (programmed death-1). However, patients experience heterogeneous outcomes with ipilimumab, including rapid or delayed progression, and it is unclear whether patterns of ipilimumab progress...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Cancer Immunol Res |
|---|---|
| Prif Awduron: | , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4940026/ https://ncbi.nlm.nih.gov/pubmed/27197063 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2326-6066.CIR-15-0281 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|